5 Cancer Research Stories Worth Following – Summer 2015

Posted by

What’s exciting in cancer research right now? In this post, I’ll review several of the most interesting cancer research stories that have been in the news this Summer.

These are a few of the recent stories that seem to have the greatest potential impact, at least from my perspective, and that I know I’ll want to follow as they develop further.

The American Society of Clinical Oncology (ASCO) held its annual meeting in June. A major theme reflected in numerous reports about the meeting was the need for more intensive efforts to match patients with treatments based on the molecular characteristics of their cancer, and incorporating this approach into clinical trials.

Targeted Treatments: Metastatic Breast Cancer

The concept of matching patients to clinical trials based on the molecular characteristics of their tumors is beginning to be applied more now in metastatic breast cancer. “For women with metastatic breast cancer, progress has been made by emphasizing the concerted efforts to evaluate treatments in subgroups rather than designing trials for “all-comers”, Dr. Don Dizon wrote in the BCSM blog.

One of the widely-reported highlights of the ASCO meeting was the findings of a clinical trial called PALOMA3. The results of the trial were reported in the New England Journal of Medicine.

The trial tested a new combination treatment for women with hormone receptor-positive, HER2-negative advanced breast cancer, whose cancer had progressed with one prior form of hormone therapy. The combination therapy included the targeted therapy Ibrance (palbociclib) along with Faslodex (fulvestrant), a hormone therapy that has been a standard treatment in this situation. (Ibrance became the first in a category of drugs known as CDK 4/6 inhibitors to be approved by the FDA in early 2015.)

The targeted combination therapy was found to more than double the average time to disease progression compared to treatment with just fulvestrant. In view of the trial results, the combination is a new standard of care available for this patient group, said Dr. Dizon.

Immunotherapy: Testing New Combination Treatments

As we discussed in the Spring 2015 edition, researchers are beginning to find that using immune system therapies in combination treatments, rather than as individual therapies, can increase their effectiveness. Unfortunately, they are also finding that sometimes the combinations can involve severe side effects.

One of the clinical trials reported at ASCO was for such a combination treatment for advanced melanoma. The two treatments in the combination had already been approved individually for advanced melanoma, but had not been tested together. One of the drugs was Opdivo (nivolumab), a PD-1 inhibitor–which works by “releasing the brakes” on the immune system. The other was Yervoy (ipulumimab), another targeted therapy of a different type that is currently standard of care for advanced melanoma. The results of the trial were reported in the New England Journal of Medicine.

The combination therapy was found to be much more effective than ipulumimab alone in extending survival without progression of the disease. Unfortunately, it was also more toxic, with over half of patients on the combined therapy experiencing severe side effects. Financial toxicity is also an issue, with the cost of the combined treatment expected to be at least $200,000 per patient, according to Medical News Today.

Given these results, “researchers say it is important that future research determines which cancer patients would be most likely to benefit from immunotherapy,” according to Medical News Today.

Immunotherapy: Finding Biomarkers for Effectiveness

Results like those for the Opdivo-Yervoy trial that show some immunotherapy treatments to be more effective but also more toxic seem to underline the importance of finding biomarkers to identify which patients will be most likely to benefit.

As an example of one such effort to identify biomarkers, MedPageToday reported on a small study presented at ASCO which “provides a different perspective about immunotherapeutic approaches to treating cancer.”

The study found that colorectal cancer patients whose tumors had a genetic deficiency referred to as “mismatch repair deficiency” had much better response to treatment with Keytruda (pembrolizumab), a so-called PD-1 inhibitor, than those whose tumors did not have that particular deficiency.

Precision Medicine: Clinical Trials

A major clinical trial testing targeted therapies based on the molecular characteristics of a patient’s tumor–rather than the organ in which it originated–opened for enrollment this month. The trial is called NCI-Molecular Analysis for Therapy Choice or “NCI-MATCH”.

The initiative will screen about 3,000 patients across the United States with many different types of cancer, with the goal of identifying about 1,000 whose tumor biopsy samples show that certain specific molecular characteristics are present. Patients will be matched with sub-trials designed to test the efficacy of drug therapies targeted specifically to these characteristics.

The initiative will start with ten sub-trials, and is expected to expand to at least twenty eventually, with 30 to 35 patients enrolled in each.

One of the goals of the trial is for at least 25 percent of the trial participants to have rare cancers, which are difficult to study in traditional clinical trials that require large numbers of patients with one type of cancer.

For more on NCI-MATCH and its implications, two very informative articles are NCI-MATCH Trial Opens in the AACR Blog and Pioneering Trial Targets Multiple Solid-Tumor Cancers with Precision Medicine from Cleveland Clinic.

Post-Treatment Monitoring

Researchers have developed a new approach to very early identification of cancer that is at high risk for relapse.  The results of their research were reported in the journal Nature Communications.

In this new approach, patients could potentially be monitored using a type of high resolution MRI, along with a contrast agent.  The contrast agent attaches itself to a substance called fibronectin that is present in large amounts in breast cancer micrometastases that are aggressive and at high risk for developing into full-blown metastases.

Studies using the approach in animal models have been very promising and the researchers hope to move forward with clinical trials within the next three years.

That’s it for this time. If there was another recent cancer research story or article that caught your attention or if you have thoughts on any of what I’ve included, I’d love to hear from you!

Related Posts
5 Cancer Research Stories Worth Following – Spring 2015
6 Cancer Research Stories Worth Following – Winter 2015

Photo by Lisa DeFerrari


  1. As a breast cancer survivor of four years (and counting), I really appreciate your post on new treatments, research, and all things survivorship related. I try and keep up with study abstracts, but learn something every time your blog comes out. Many many thanks.

    1. Thank you very much, Shirlee. I always enjoy putting the posts together because it is such a great learning process for me. But it really shouldn’t be as hard as it is for the average interested person to keep up with what’s going on in this area. Thanks so much for your comments!

  2. This is very helpful, thank you so much for collecting all the latest information on treatments. It’s amazing how there’s so much happening in research that many of us are unaware of. I usually don’t spend too much time researching but it is important to stay up-to-date, especially because we never know when we have to face this monster again. It’s nice of you to take on the responsibility of doing the research for all of us.

    1. Hi, Rebecca. I try to spend a little time each day scanning the research news & sharing the best on TW and/or FB. I agree, it is amazing how much is happening in research, and it’s always very hard to choose just a few items to write about. Thanks a lot for letting me know that you’re finding this summary helpful!

Comments are closed.